Hepatobiliary elimination of bile acid-modified oligodeoxynucleotides in Wistar and TR- rats: Evidence for mrp2 as carrier for oligodeoxynucleotides

Biochemical Pharmacology

Volumn 66, Issue 4, 2003, Pages 565-577

  Lischka, Kerstin ^a   Starke, Dieter ^a   Failing, Klaus ^a   Herling, Andreas ^b   Kramer, Werner ^b   Petzinger, Ernst ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Bile acids; Bile salt export pump; Liver evasion; Liver targeting; mrp2; Oligodeoxynucleotides

Indexed keywords

BILE ACID; BROMSULFOPHTHALEIN; CHLOROGENIC ACID; CHOLIC ACID; COMPLEMENTARY RNA; ESTER DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 2; OLIGONUCLEOTIDE; PHOSPHODIESTER; PHOSPHOROTHIOIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EXCRETION; LIVER CLEARANCE; MALE; MEMBRANE; MOLECULE; MULTIDRUG RESISTANCE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE;

EID: 0142039147     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00339-3     Document Type: Article

References (46)

1. Uhlmann E., Peyman A. Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90:1990;544-584.
2. Milligan J.F., Matteucci M.D., Martin J.C. Current concepts in antisense drug design. J. Med. Chem. 36:1993;1923-1937.
3. Agrawal S., Zhao Q. Antisense therapeutics. Curr. Opin. Chem. Biol. 2:1998;519-528.
4. 14C ]-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats J. Pharmacol. Exp. Ther. 267:1993;1181-1190.
5. 3H ]-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate Mol. Pharmacol. 45:1994;932-943.
6. Agrawal S., Temsamani J., Galbraith W., Tang J. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28:1995;7-16.
7. Nolting A., DeLong R.K., Fisher M.H., Wickstrom E., Pollack G.M., Juliano R.L., Brouwer K.L.A.R. Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver. Pharm. Res. 14:1997;516-521.
8. Petzinger E., Wickboldt A., Pagels P., Starke D., Kramer W. Hepatobiliary transport of bile acid amino acid, bile acid peptide, and bile acid oligonucleotide conjugates in rats. Hepatology. 30:1999;1257-1268.
9. Keppler D., König J. Hepatic secretion of conjugated and endogenous substances. Semin. Liver Dis. 20:2000;267-272.
10. Kullak-Ublick G.A., Beuers U., Paumgartner G. Hepatobiliary transport. J. Hepatol. 32:2000;3-18.
11. Kipp H., Arias I.M. Trafficking of canalicular ABC transporters in hepatocytes. Annu. Rev. Physiol. 64:2002;595-608.
12. Paulusma C.C., Oude Elferink R.P.J. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J. Mol. Med. 75:1997;420-428.
13. Meier P.J., Stieger B. Bile salt transporters. Annu. Rev. Physiol. 64:2002;635-661.
14. Starke D., Lischka K., Pagels P., Uhlmann E., Kramer W., Wess G., Petzinger E. Bile acid-oligonucleotide conjugates: synthesis and liver excretion in rats. Bioorg. Med. Chem. Lett. 11:2001;945-949.
15. Hemmerle H., Burger H.J., Below P., Schubert G., Rippel R., Schindler P.W., Paulus E., Herling A.W. Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. J. Med. Chem. 40:1997;137-145.
16. Hagenbuch B., Scharschmidt B.F., Meier P.J. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem. J. 316:1996;901-904.
17. Dixon WJ. BDMP - statistical software manual, vols. 1 and 2. Berkely, LA: University of California Press; 1993.
18. Büchler M., König J., Brom M., Kartenbeck J., Spring H., Horie T., Keppler D. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271:1996; 15091-15098.
19. Keppler D., König J. Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene. FASEB J. 11:1997;509-516.
20. -) by the glucose-6-phosphate translocase inhibitor S 3025. Biochim. Biophys. Acta. 1569:2002;105-110.
21. Müller M., Meijer C., Zaman G.J.R., Borst P., Scheper R.J., Mulder N.H., DeVries E.G.E., Jansen P.L.M. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U.S.A. 91:1994;13033-13037.
22. Keppler D., Jedlitschky G., Leier I. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol. 292:1998;607-616.
23. 4 and structurally related conjugates. J. Biol. Chem. 269:1994;27807-27810.
24. - rats with hepatobiliary secretion defect. Am J Physiol 1993;265 (Gastrointest Liver Physiol 28):G445-52.
25. - rats with hepatobiliary secretion defect. Am J Physiol 1993;265 (Gastrointest Liver Physiol 28):G445-52.
26. - rats. J. Hepatol. 31:1999;678-684.
27. Gerloff T., Stieger B., Hagenbuch B., Madon J., Landmann L., Roth J., Hofmann A.F., Meier P.J. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273:1998;10046-10050.
28. Stieger B., Fattinger K., Madon J., Kullak-Ublick G.A., Meier P.J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 118:2000;422-430.
29. Childs S., Yeh R.L., Hui D., Ling V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res. 58:1998;4160-4167.
30. Lecureur V., Sun D., Hargrove P., Schuetz E.G., Kim R.B., Lan L.B., Schuetz J.D. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol. Pharmacol. 57:2000;24-35.
31. Vlassow V.V., Balakireva L., Yakubov L.A. Transport of oligonucleotides across natural and model membranes. Biochim. Biophys. Acta. 1197:1994;95-108.
32. Lu X.M., Fischmann A.J., Jyawook S.L., Hendricks K., Tompkins R.G., Yarmush M.L. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J. Nucl. Med. 35:1994;269-275.
33. Mahato R.I., Takemura S., Akamatsu K., Nishikawa M., Takakura Y., Hashida M. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem. Pharmacol. 53:1997;887-895.
34. Bijsterbosch M.K., Manoharan M., Rump E.T., DeVrueh R.L.A., Van Veghel R., Tivel K.L., Biessen E.A.L., Bennett C.F., Cook P.D., Van Berkel T.J.C. In vivo fate of phophorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res. 25:1997;3290-3296.
35. Butler M., Crooke R.M., Graham M.J., Lemonidis K.M., Lougheed M., Murray S.F., Witchell D., Steinbrecher U., Bennett C.F. Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. J. Pharmacol. Exp. Ther. 292:2000;489-496.
36. Tondelli R., Ricca A., Laus M., Lelli M., Citro G. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res. 26:1998;5425-5431.
37. Alahari S.K., DeLong R., Fisher M.H., Dean N.M., Viliet P., Juliano R.L. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J. Pharmacol. Exp. Ther. 286:1998;447-454.
38. Bennett C.F., Chiang M.Y., Chan H., Shoemaker J.E.E., Mirabelli C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1992;1023-1033.
39. Bennett C.F., Condon T.P., Grimm S., Chan H., Chiang M.Y. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol. 152:1994;3530-3540.
40. Dean N.M., McKay R., Condon T.P., Bennett C.F. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligodeoxynucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM) mRNA by phorbol esters. J. Biol. Chem. 269:1994;16416-16424.
41. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:2000;1295-1302.
42. Borst P., Oude Elferink R.P.J. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71:2002;537-592.
43. Krieg M.A., Tonkinson J., Matson T., Zhao Q., Saxon M., Zhang L.-M., Bhanja U., Yakubov L., Stein C.A. Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improved efficacy. Proc. Natl. Acad. Sci. U.S.A. 90:1993;1048-1052.
44. Wu G.Y., Wu C.H. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267:1992;12436-12439.
45. Offensperger W.-B., Offensperger S., Blum H.E. Antisense therapy of hepatitis B virus infection. Mol. Biotechnol. 9:1998;161-170.
46. Nakazono K., Ito Y., Wu C.H., Wu G.Y. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology. 23:1996;1297-1303.